• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Danimer Scientific Inc.

    11/14/24 3:28:09 PM ET
    $DNMR
    Major Chemicals
    Industrials
    Get the next $DNMR alert in real time by email
    SC 13G 1 armistice-dnmr093024.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    DANIMER SCIENTIFIC, INC.

    (Name of Issuer)

     

    Class A Common stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    236272100

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  236272100
     SCHEDULE 13G
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    12,018,677
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    12,018,677
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    12,018,677
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.90%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  236272100
     SCHEDULE 13G
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    12,018,677
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    12,018,677
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    12,018,677
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.90%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 236272100
     SCHEDULE 13G
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    DANIMER SCIENTIFIC, INC.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    140 Industrial Boulevard

    Bainbridge, Georgia 39817

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Class A Common stock, $0.0001 par value per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    236272100

     

    CUSIP No.  236272100
     SCHEDULE 13G
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 236272100
     SCHEDULE 13G
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of September 30, 2024:

    Armistice Capital, LLC - 12,018,677

    Steven Boyd - 12,018,677   

    (b) Percent of Class as of September 30, 2024:

    Armistice Capital, LLC - 9.90%

    Steven Boyd - 9.90% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 12,018,677

    Steven Boyd - 12,018,677  

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 12,018,677

    Steven Boyd - 12,018,677

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 236272100
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 236272100
     SCHEDULE 13G
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $DNMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNMR

    DatePrice TargetRatingAnalyst
    11/21/2024$40.00 → $5.50Hold
    TD Cowen
    11/20/2024$40.00 → $4.00Neutral → Underweight
    Piper Sandler
    8/13/2024$2.00 → $1.00Buy → Hold
    TD Cowen
    5/22/2024$1.30 → $0.80Buy → Hold
    Jefferies
    4/9/2024$3.50 → $1.25Overweight → Neutral
    Piper Sandler
    10/12/2022$4.50Overweight
    Piper Sandler
    9/23/2021$21.00Outperform
    Cowen
    More analyst ratings

    $DNMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Danimer Scientific Inc.

      SC 13G - Danimer Scientific, Inc. (0001779020) (Subject)

      11/14/24 3:28:09 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Danimer Scientific Inc.

      SC 13G/A - Danimer Scientific, Inc. (0001779020) (Subject)

      7/8/24 4:36:39 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • SEC Form SC 13G/A filed by Danimer Scientific Inc. (Amendment)

      SC 13G/A - Danimer Scientific, Inc. (0001779020) (Subject)

      1/29/24 5:25:54 PM ET
      $DNMR
      Major Chemicals
      Industrials

    $DNMR
    Financials

    Live finance-specific insights

    See more
    • Danimer Scientific Announces Common Stock Expected to Begin Trading Promptly on OTCQX Marketplace

      –Dividend warrants continue to trade on OTCQX marketplace under "DNMRW"– Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced that it received notice the New York Stock Exchange ("NYSE") suspended trading of its common stock on the NYSE effective immediately and started the process to delist its common stock from the NYSE. The start of the delisting process follows the NYSE's determination under Rule 802.01B of the NYSE Listed Company Manual that the Company did not meet the continued listing standard that requires listed companies to maintain a

      12/31/24 8:00:00 AM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific Announces Third Quarter 2024 Results

      --Additional Resin Orders and Deliveries Continue to Support 20-Million Pound Cutlery Award –- -- 100% Compostable Skittles® Bag Made with Nodax® PHA Featured at NFL Game -- Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today financial results for its third quarter ended September 30, 2024. Richard N. Altice, Interim Chief Executive Officer of Danimer, commented, "We completed the third quarter in line with our expectations considering the temporary impact of Starbucks' reapportionment of their Nodax-based straw business between our convert

      11/19/24 8:30:00 AM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific Announces Release Date for Third Quarter 2024 Results

      Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading, next-generation bioplastics company focused on the development and production of biodegradable materials, announced today that the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 19, 2024. A webcast and conference call will be held that same day at 10:00 a.m. Eastern Time to review the Company's third quarter results. The webcast of the conference will be accessible on the Investor Relations section of the Company's website at https://ir.danimerscientific.com. For those unable to access the webcast, the conference call will be accessible domestically o

      11/14/24 9:00:00 AM ET
      $DNMR
      Major Chemicals
      Industrials

    $DNMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Danimer Scientific Announces New Directors

      Dr. David Moody and Richard Altice to Join the Danimer Board Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading, next-generation bioplastics company focused on the production of biodegradable materials, is pleased to announce that Dr. David Moody and Mr. Richard Altice have been appointed as members of Danimer's Board of Directors. Dr. Moody's appointment is effective immediately, and Mr. Altice's appointment is effective as of April 15, 2024. Dr. David J. Moody currently is a member of the Board of Directors of Jadex Inc., a US-based manufacturing and material science company utilizing innovation and technology to develop sustainable products that serve the me

      1/18/24 4:30:00 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific Appoints Stephen Martin as Chief Legal Officer and Corporate Secretary

      Martin, a Duke University graduate and former Air Force officer, brings experience managing the legal affairs of publicly traded companies Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next-generation bioplastics company focused on the development and production of biodegradable materials, today announced it has appointed Stephen Martin as Chief Legal Officer and Corporate Secretary. In this role, Martin will manage a wide range of legal matters across the company as Danimer continues to expand its manufacturing capacity to meet demand in the fast-growing bioplastics market. Martin joins Danimer from Kaman Distribution Group, a leading national distributor o

      9/20/22 8:30:00 AM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific Appoints Anthony Austin as Chief Human Resource Officer

      Austin brings more than 30 years of human resources leadership experience with PepsiCo, Delta Air Lines, Winn-Dixie and others Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next-generation bioplastics company focused on the development and production of biodegradable materials, today announced it has appointed Anthony Austin as Chief Human Resource Officer. In this role, Austin will focus on building best-in-class HR processes to strategically support the Company's growth as it continues to expand its manufacturing capacity. Austin joins Danimer from Bedrock Manufacturing Co., the parent company of Shinola, a luxury watch, leather and jewelry manufacturer an

      4/20/22 8:00:00 AM ET
      $DNMR
      Major Chemicals
      Industrials

    $DNMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Hajost Michael A converted options into 859 shares and covered exercise/tax liability with 301 shares, increasing direct ownership by 31% to 2,334 units (SEC Form 4)

      4 - Danimer Scientific, Inc. (0001779020) (Issuer)

      2/10/25 4:30:05 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • Director Moody David Jesse converted options into 646 shares (SEC Form 4)

      4 - Danimer Scientific, Inc. (0001779020) (Issuer)

      1/21/25 4:30:10 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • SEC Form 4 filed by Director Croskrey Stephen

      4 - Danimer Scientific, Inc. (0001779020) (Issuer)

      1/3/25 4:05:07 PM ET
      $DNMR
      Major Chemicals
      Industrials

    $DNMR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hendrix Richard J bought $93,395 worth of shares (100,000 units at $0.93) (SEC Form 4)

      4 - Danimer Scientific, Inc. (0001779020) (Issuer)

      11/28/23 5:35:32 PM ET
      $DNMR
      Major Chemicals
      Industrials

    $DNMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Danimer Scientific Announces Common Stock Expected to Begin Trading Promptly on OTCQX Marketplace

      –Dividend warrants continue to trade on OTCQX marketplace under "DNMRW"– Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced that it received notice the New York Stock Exchange ("NYSE") suspended trading of its common stock on the NYSE effective immediately and started the process to delist its common stock from the NYSE. The start of the delisting process follows the NYSE's determination under Rule 802.01B of the NYSE Listed Company Manual that the Company did not meet the continued listing standard that requires listed companies to maintain a

      12/31/24 8:00:00 AM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific Takes Action to Strengthen Capital Structure

      Announces Issuance of $11,250,000 Super Senior Secured Promissory Note Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced that the Company issued a super senior secured promissory note (the "Secured Loan") in an aggregate principal amount of $11,250,000 to certain lenders under its existing term loan financing agreement, as well as certain additional lenders. The Secured Loan provides for $11,250,000 gross proceeds, less fees and expenses. The Secured Loan has a two-year maturity and accrues interest at 15.0% per annum, which interest is payab

      12/17/24 4:15:00 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • TerraNova Capital Equities announces three transactions totaling $45 Million

      NEW YORK, Nov. 20, 2024 /PRNewswire/ -- TerraNova Capital Equities, inc. (TerraNova), a leading financial advisory firm, is pleased to announce that its Structure Finance Group acted as sole advisor on three recent transactions: TerraNova Structured Finance Group acted as the sole advisor to Danimer Scientific, Inc. (NYSE:DNMR) on a $20 Million revolving credit facility. TerraNova is pleased to announce its role as the exclusive advisor to Danimer Scientific in securing a strategic ABL agreement with Mountain Ridge Capital.  This $20 million facility, collateralized by the Com

      11/20/24 10:30:00 AM ET
      $DNMR
      $INUV
      Major Chemicals
      Industrials
      Advertising
      Consumer Discretionary

    $DNMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen reiterated coverage on Danimer Scientific with a new price target

      TD Cowen reiterated coverage of Danimer Scientific with a rating of Hold and set a new price target of $5.50 from $40.00 previously

      11/21/24 8:09:13 AM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Danimer Scientific from Neutral to Underweight and set a new price target of $4.00 from $40.00 previously

      11/20/24 9:49:17 AM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific downgraded by TD Cowen with a new price target

      TD Cowen downgraded Danimer Scientific from Buy to Hold and set a new price target of $1.00 from $2.00 previously

      8/13/24 7:29:01 AM ET
      $DNMR
      Major Chemicals
      Industrials

    $DNMR
    SEC Filings

    See more
    • Danimer Scientific Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

      8-K - Danimer Scientific, Inc. (0001779020) (Filer)

      3/18/25 5:00:42 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • Danimer Scientific Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Danimer Scientific, Inc. (0001779020) (Filer)

      2/28/25 5:00:09 PM ET
      $DNMR
      Major Chemicals
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Danimer Scientific Inc.

      SCHEDULE 13G/A - Danimer Scientific, Inc. (0001779020) (Subject)

      2/14/25 5:41:32 PM ET
      $DNMR
      Major Chemicals
      Industrials